Welcome to GLIOTRAIN

Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics



An estimated 240,000 cases of brain and nervous system tumours are diagnosed every year, worldwide and Glioblastoma (GBM) is the most frequent and aggressive brain tumour. New treatment options and effective precision medicine therapies are urgently required. GLIOTRAIN is a multi-sectoral industry-academia collaboration, funded by the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie ITN initiative, that will work to identify novel strategies to treat GBM as well as investigating resistance mechanisms in this devastating disease.

Latest news

GLIOTRAIN consortium members, the University of Stuttgart and YUMAB, awarded grant to establish new approaches in Targeted Drug Delivery to the Brain

GLIOTRAIN investigators Professor Markus Morrison and Dr Gavin Fullstone, from the University of Stuttgart, along with GLIOTRAIN industry partner YUMAB and other partners have been awarded a grant from the Federal Ministry of Education and Research (BMBF, Germany) on the theme of Targeted Drug Delivery.

The Team